Browse VPS29

Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Membrane; Peripheral membrane protein. Endosome membrane Peripheral membrane protein Early endosome Late endosome
Domain PF12850 Calcineurin-like phosphoesterase superfamily domain
Function

Acts as component of the retromer cargo-selective complex (CSC). The CSC is believed to be the core functional component of retromer or respective retromer complex variants acting to prevent missorting of selected transmembrane cargo proteins into the lysosomal degradation pathway. The recruitment of the CSC to the endosomal membrane involves RAB7A and SNX3. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX3-retromer mediates the retrograde endosome-to-TGN transport of WLS distinct from the SNX-BAR retromer pathway. The SNX27-retromer is believed to be involved in endosome-to-plasma membrane trafficking and recycling of a broad spectrum of cargo proteins. The CSC seems to act as recruitment hub for other proteins, such as the WASH complex and TBC1D5. Required to regulate transcytosis of the polymeric immunoglobulin receptor (pIgR-pIgA) (Probable). Involved in GLUT1 endosome-to-plasma membrane trafficking; the function is dependent of association with ANKRD27 (PubMed:24856514).

> Gene Ontology
 
Biological Process GO:0007034 vacuolar transport
GO:0016055 Wnt signaling pathway
GO:0016197 endosomal transport
GO:0016482 cytosolic transport
GO:0042147 retrograde transport, endosome to Golgi
GO:0098876 vesicle-mediated transport to the plasma membrane
GO:0198738 cell-cell signaling by wnt
GO:1990126 retrograde transport, endosome to plasma membrane
Molecular Function GO:0008565 protein transporter activity
Cellular Component GO:0005769 early endosome
GO:0005770 late endosome
GO:0010008 endosome membrane
GO:0030904 retromer complex
GO:0030906 retromer, cargo-selective complex
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-3238698: WNT ligand biogenesis and trafficking
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VPS29 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VPS29 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.37; FDR: 0.02150 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VPS29 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2120.298
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2530.928
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1870.925
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0420.907
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4460.798
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4690.833
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3170.408
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2170.901
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4320.824
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1850.956
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1740.0013
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VPS29. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VPS29. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VPS29.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VPS29. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VPS29 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VPS29 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVPS29
NameVPS29 retromer complex component
Aliases PEP11; DC15; vacuolar protein sorting 29 (yeast homolog); vacuolar protein sorting 29 (yeast); vacuolar prot ......
Chromosomal Location12q24.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VPS29 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.